Technical Analysis for MRUS - Merus N.V.

Grade Last Price % Change Price Change
D 23.06 -0.99% -0.23
MRUS closed down 0.99 percent on Friday, April 9, 2021, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Up
Historical MRUS trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Crossed Above 50 DMA Bullish -0.99%
Narrow Range Bar Range Contraction -0.99%
NR7 Range Contraction -0.99%
Older End-of-Day Signals for MRUS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support 2 days ago
60 Minute Opening Range Breakout 2 days ago
50 DMA Resistance 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Merus N.V. Description

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Monoclonal Antibodies Cancer Immunotherapy Ovarian Cancer Acute Myeloid Leukemia Myelodysplastic Syndrome Ovarian Cancers Monoclonal Antibody Therapy Oncology Applications Europe Novimmune Treatment Of Myelodysplastic Syndrome

Is MRUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.2712
52 Week Low 10.18
Average Volume 142,574
200-Day Moving Average 16.97
50-Day Moving Average 23.15
20-Day Moving Average 22.05
10-Day Moving Average 21.82
Average True Range 1.61
ADX 16.58
+DI 17.59
-DI 17.64
Chandelier Exit (Long, 3 ATRs ) 20.01
Chandelier Exit (Short, 3 ATRs ) 23.18
Upper Bollinger Band 24.34
Lower Bollinger Band 19.75
Percent B (%b) 0.72
BandWidth 20.84
MACD Line -0.02
MACD Signal Line -0.28
MACD Histogram 0.2606
Fundamentals Value
Market Cap 670.79 Million
Num Shares 29.1 Million
EPS -1.94
Price-to-Earnings (P/E) Ratio -11.88
Price-to-Sales 17.39
Price-to-Book 6.04
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.99
Resistance 3 (R3) 24.00 23.70 23.84
Resistance 2 (R2) 23.70 23.46 23.70 23.78
Resistance 1 (R1) 23.38 23.32 23.23 23.37 23.73
Pivot Point 23.08 23.08 23.01 23.08 23.08
Support 1 (S1) 22.76 22.84 22.61 22.75 22.39
Support 2 (S2) 22.46 22.70 22.46 22.34
Support 3 (S3) 22.14 22.46 22.29
Support 4 (S4) 22.13